Reaching beyond boundaries: how R&D is expanding indications across obesity, oncology and cell and gene therapy 

In drug development today, therapies originally designed for one disease being reimagined for broader use. Obesity treatments are becoming whole‑body therapeutics with cardiometabolic and psychiatric ambitions, for example. In gynecologic oncology, the emergence of checkpoint inhibitors alongside a growing field of antibody-drug conjugates is reshaping study design and bringing nuanced treatment sequencing decisions to the… The post Reaching beyond boundaries: how R&D is expanding indications across obesity, oncology and cell and gene therapy  appeared first on Drug Discovery and Development.

Continue reading →